| Dr Steven Harold Goldberg, MD | |
|
1970 S Ridge Rd, Green Bay, WI 54304-4125 | |
| (920) 430-4888 | |
| (920) 430-4889 |
| Full Name | Dr Steven Harold Goldberg |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 24 Years |
| Location | 1970 S Ridge Rd, Green Bay, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174566194 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207XS0106X | Orthopaedic Surgery - Hand Surgery | 49122-20 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Bellin Memorial Hospital | Green bay, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bellin Memorial Hospital Inc | 8820900749 | 513 |
News Archive
Bacteria are bad. Mothers and doctors, not to mention the cleaning product industry, repeatedly warn of their dangers. But a Stanford University School of Medicine microbiologist is raising the intriguing idea that persistent bacterial and viral infections have benefits.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.
An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.
Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.
› Verified 2 days ago
| Entity Name | Bellin Memorial Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609838473 PECOS PAC ID: 8820900749 Enrollment ID: O20031121000089 |
News Archive
Bacteria are bad. Mothers and doctors, not to mention the cleaning product industry, repeatedly warn of their dangers. But a Stanford University School of Medicine microbiologist is raising the intriguing idea that persistent bacterial and viral infections have benefits.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.
An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.
Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.
› Verified 2 days ago
| Entity Name | Oconto Hospital & Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356373302 PECOS PAC ID: 2163461781 Enrollment ID: O20050713000836 |
News Archive
Bacteria are bad. Mothers and doctors, not to mention the cleaning product industry, repeatedly warn of their dangers. But a Stanford University School of Medicine microbiologist is raising the intriguing idea that persistent bacterial and viral infections have benefits.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.
An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.
Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Harold Goldberg, MD Po Box 22487, Green Bay, WI 54305-2487 Ph: (920) 445-7222 | Dr Steven Harold Goldberg, MD 1970 S Ridge Rd, Green Bay, WI 54304-4125 Ph: (920) 430-4888 |
News Archive
Bacteria are bad. Mothers and doctors, not to mention the cleaning product industry, repeatedly warn of their dangers. But a Stanford University School of Medicine microbiologist is raising the intriguing idea that persistent bacterial and viral infections have benefits.
"Senotherapy," a treatment that uses small molecule drugs to target "senescent" cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, Ph.D., a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.
MSD announced today that the European Commission has approved the Marketing Authorization Application (MAA) for SYCREST® (asenapine) sublingual tablets for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. Today's decision was based on recommendations from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). The Commission Decision applies to all 27 European Member States.
An analysis of immune markers measured in a sub-study of ViroStatics' proof-of-concept Phase 2a trial showed that VS411 was able to reduce immune activation while producing a median 1.5 log10 reduction in viral load.
Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the measurement of G protein-coupled receptor (GPCR) activation electrical impedance represents an excellent universal readout technology, since different signaling pathways can be measured in one assay format using recombinant as well as primary cells.
› Verified 2 days ago
William Victor Albiero, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2223 Lime Kiln Rd Ste 1, Green Bay, WI 54311 Phone: 920-430-8113 | |
William J. Enright, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2223 Lime Kiln Rd, Green Bay, WI 54311 Phone: 920-468-0246 Fax: 920-432-9309 | |
Rolf Smart Lulloff, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 1715 Dousman St, Green Bay, WI 54303 Phone: 920-496-4700 Fax: 920-496-4747 | |
Mr. Thomas Andrew Sullivan, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2223 Lime Kiln Rd, Suite 1, Green Bay, WI 54311 Phone: 920-430-8120 Fax: 920-430-8122 | |
Dr. Michael K Ryan, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1726 Shawano Ave, Green Bay, WI 54303 Phone: 920-496-4700 | |
Michael Jameson Florack, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 1821 S Webster Ave, Green Bay, WI 54301 Phone: 920-496-4700 Fax: 920-431-1972 |